A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months
ASCVD is a global concern as it has become central to significant morbidity and mortality. LDL-C is the most important modifiable risk factor in developing ASCVD. Therefore, lowering LDL-C levels is paramount to tackling ASCVD; the lower the LDL-C, the better. Finding the right combination of medica...
Saved in:
| Main Authors: | Carl Deaney, Meredith Donaldson, Agne Meskauskiene |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Online Access: | https://doi.org/10.1177/11795468251337425 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Driving Sustainability in Asthma and COPD Management: Preventative Models and Green Prescribing in a Rural Primary Care Practice in England
by: Meredith Donaldson, et al.
Published: (2025-04-01) -
Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024-11-01) -
Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01) -
Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
by: E. A. Medvedeva, et al.
Published: (2023-05-01) -
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
by: Lin Zhang, et al.
Published: (2025-02-01)